Zentalis Pharmaceuticals(NASDAQ) ZNTL

Zentalis makes new medicines to help people fight cancer. The company focuses on pills that stop tumors from growing. These treatments help patients with advanced solid tumors.

Fighting Cancer with Small Molecules

• Azenosertib: Oral pill designed to block WEE1, a protein that helps cancer cells repair their DNA.
• ZN-c5: Selective estrogen receptor degrader currently in trials for advanced or metastatic breast cancer.
• ZN-d5: Selective inhibitor targeting B-cell lymphoma 2 for treating non-Hodgkin's lymphoma and leukemia.
• ZN-e4: Irreversible inhibitor developed to treat patients with advanced non-small cell lung cancer.

Recent Moves and Partnerships

• Dosed the first patient in the Phase 3 ASPENOVA trial for ovarian cancer in May 2026.
• Triggered a $7 million milestone payment to Recurium IP Holdings in May 2026 following trial progress.
• Reduced workforce by 40% in January 2025 to prioritize the development of azenosertib and extend cash resources.
• Maintained strategic collaborations with Pfizer and GSK to evaluate drug combinations in clinical settings.

What Makes the Tech Different

Zentalis uses a specialized biomarker strategy to identify specific ovarian cancer patients most likely to benefit from its drugs. The company holds exclusive worldwide rights to its main product candidates currently in late-stage clinical trials.

The Numbers and Cash Flow

• Net loss was $35.4 million in Q1 2026, narrowed 26.8% from $48.3 million in Q1 2025.
• Operating income was a loss of $37.9 million in Q1 2026, narrowed 17% from Q1 2025.
• Revenue reached $0 in Q1 2026, down 100% from $40.6 million in Q1 2024.
• Free cash flow hit negative $33 million in Q1 2026, deepening 1.1% from Q1 2025.

Bottom Line

Zentalis has transitioned from early research into a clinical-stage developer focused on late-stage cancer trials. Restructuring in 2025 helped the company narrow its focus and extend its cash runway into late 2027.